Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild and Moderate Hepatic Impairment
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- To study effect of mild and moderate hepatic impairment on the pharmacokinetics of
otamixaban.
Secondary Objective:
- To assess the pharmacodynamic effects of otamixaban on subjects with mild and moderate
hepatic impairment and in matched subjects with normal hepatic function.